Treatment of spondyloarthropathies with antibodies against tumour necrosis factor α:: first clinical and laboratory experiences
Treatment of spondyloarthropathies with antibodies against tumour necrosis factor α:: first clinical and laboratory experiences
复制标题
DOI:
10.1136/ard.59.12.985
复制
发表时间:
2000-11-01
影响因子:
27.4
通讯作者:
Sieper, J
中科院分区:
文献类型:
--
作者:
Braun, J;Xiang, J;Sieper, J
The spondyloarthropathies are among the most common inflammatory rheumatic diseases. 1 In addition to the strong genetic predisposition, partly due to HLA-B27, 2 there are characteristic clinical features of SpA3: inflammatory back pain often due to sacroiliitis4 and enthesitis occurring mostly at various well defined locations, predominantly of the legs, such as the Achilles tendon, the plantar aponeurosis, the knee, the trochanter regions of the femur, and several pelvic sites. 5 Thus entheses are ubiquitous, resulting in a diversity of associated pathological manifestations. Sacroiliitis is the most common early sign of SpA. 6 Whether or not ligamentous and entheseal structures are aVected in sacroiliac inflammation has not yet been entirely clarified. To answer some of the most critical questions an expert symposium on enthesitis was organised:+ Why are enthesis related structures aVected?+ Is the presence of fibrocartilage essential?+ Do we have to change the concept of enthesitis or that of enthesis? More structures are aVected than the conventional concept of enthesis implies. What about the blood supply of such structures?+ Is enthesitis an inflammatory process? Is it due to an immune response, trauma/mechanical stress, or both?+ Where does the inflammation start?+ Is the new bone formation and ankylosis a pathological process itself, or is it no more than a reaction to severe and persistent inflammation?